ALT5 Sigma (ALTS) Competitors $6.73 -0.08 (-1.17%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$6.68 -0.05 (-0.74%) As of 08/5/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALTS vs. CGEM, ERAS, PRTC, PGEN, SVRA, GOSS, CMPX, KMDA, RGNX, and PVLAShould you be buying ALT5 Sigma stock or one of its competitors? The main competitors of ALT5 Sigma include Cullinan Therapeutics (CGEM), Erasca (ERAS), PureTech Health (PRTC), Precigen (PGEN), Savara (SVRA), Gossamer Bio (GOSS), Compass Therapeutics (CMPX), Kamada (KMDA), REGENXBIO (RGNX), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. ALT5 Sigma vs. Its Competitors Cullinan Therapeutics Erasca PureTech Health Precigen Savara Gossamer Bio Compass Therapeutics Kamada REGENXBIO Palvella Therapeutics Cullinan Therapeutics (NASDAQ:CGEM) and ALT5 Sigma (NASDAQ:ALTS) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability. Does the media prefer CGEM or ALTS? In the previous week, Cullinan Therapeutics had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 2 mentions for Cullinan Therapeutics and 0 mentions for ALT5 Sigma. Cullinan Therapeutics' average media sentiment score of 0.67 beat ALT5 Sigma's score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cullinan Therapeutics Positive ALT5 Sigma Neutral Which has better valuation & earnings, CGEM or ALTS? ALT5 Sigma has higher revenue and earnings than Cullinan Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCullinan TherapeuticsN/AN/A-$167.38M-$2.91-2.78ALT5 Sigma$12.53M10.82-$6.24MN/AN/A Which has more volatility & risk, CGEM or ALTS? Cullinan Therapeutics has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Do institutionals & insiders hold more shares of CGEM or ALTS? 86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 6.1% of Cullinan Therapeutics shares are held by insiders. Comparatively, 4.9% of ALT5 Sigma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is CGEM or ALTS more profitable? Cullinan Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -38.58%. Cullinan Therapeutics' return on equity of -29.47% beat ALT5 Sigma's return on equity.Company Net Margins Return on Equity Return on Assets Cullinan TherapeuticsN/A -29.47% -28.19% ALT5 Sigma -38.58%-113.79%-8.96% Do analysts recommend CGEM or ALTS? Cullinan Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 271.29%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cullinan Therapeutics is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCullinan Therapeutics beats ALT5 Sigma on 9 of the 13 factors compared between the two stocks. Get ALT5 Sigma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricALT5 SigmaFIN IndustryFinance SectorNASDAQ ExchangeMarket Cap$137.17M$7.57B$12.10B$9.53BDividend YieldN/A4.91%5.65%4.14%P/E RatioN/A19.4119.8923.88Price / Sales10.824.9326.1498.82Price / CashN/A20.5721.3158.35Price / Book13.732.602.125.60Net Income-$6.24M$310.82M$1.00B$265.26M7 Day Performance8.03%0.77%0.36%-0.14%1 Month Performance-19.69%8.78%0.13%6.08%1 Year Performance398.52%36.40%544.27%24.22% ALT5 Sigma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSALT5 SigmaN/A$6.73-1.2%N/A+413.7%$137.17M$12.53M0.00170CGEMCullinan Therapeutics2.1776 of 5 stars$8.34+1.3%$30.00+259.7%-54.0%$485.69MN/A-2.8730ERASErasca1.9337 of 5 stars$1.55-8.8%$4.57+194.9%-41.1%$481.59MN/A-2.50120News CoverageUpcoming EarningsPRTCPureTech Health1.4566 of 5 stars$19.13-2.3%$45.00+135.3%-10.7%$470.18M$4.83M0.00100Positive NewsPGENPrecigen4.0153 of 5 stars$1.57-0.6%$6.00+282.2%+47.3%$466.38M$3.92M-2.80190Upcoming EarningsSVRASavara2.025 of 5 stars$2.62-1.5%$5.60+113.7%-31.8%$459.75MN/A-5.4620Upcoming EarningsGOSSGossamer Bio3.9407 of 5 stars$1.96-1.0%$8.25+320.9%+173.3%$450.06M$114.70M-8.52180News CoverageEarnings ReportUpcoming EarningsCMPXCompass Therapeutics2.9109 of 5 stars$3.17-0.9%$12.67+299.6%+216.1%$442.51M$850K-7.7320News CoverageUpcoming EarningsKMDAKamada4.4692 of 5 stars$7.51-2.2%$13.00+73.1%+32.2%$441.64M$160.95M25.90360Positive NewsUpcoming EarningsRGNXREGENXBIO4.1393 of 5 stars$8.41-4.3%$31.63+276.0%-33.7%$440.91M$83.33M-2.70370Upcoming EarningsPVLAPalvella Therapeutics2.7973 of 5 stars$38.88-2.5%$47.50+22.2%N/A$440.79M$42.81M-3.21N/ANews CoveragePositive NewsUpcoming EarningsAnalyst UpgradeHigh Trading Volume Related Companies and Tools Related Companies CGEM Alternatives ERAS Alternatives PRTC Alternatives PGEN Alternatives SVRA Alternatives GOSS Alternatives CMPX Alternatives KMDA Alternatives RGNX Alternatives PVLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALTS) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALT5 Sigma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ALT5 Sigma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
